XTend Medical Updates Shareholders on Company’s Operational Plans

SUN VALLEY, CA--(Marketwire - December 21, 2009) -

XTend Medical, (PINKSHEETS: XMDC), a company that specializes in delivering life changing medical technology to healthcare organizations globally, released the following information to update their shareholders on the company’s operational plans moving forward:

“Now that we’ve completed the purchase of the BioHarp, the company has a clear path it will take to deliver this cutting-edge product to the healthcare community globally. Our intentions are to do the following:

1. Finalize the end product design relating to the device and software. This has already been agreed upon by management and we will look to have the finished product very shortly to begin sales to the veterinary, equine, and horticulture sectors.

2. Secure our manufacturing contracts so we can meet our anticipated needs of 20-30,000 units per month for 2010. (This number could rise dramatically based on our current contract conversations with several health organizations globally.)

3. Amend our KFDA application with the adjustments made to the device and software. Expected approval is within six-eight weeks for anticipated sales in South Korea.

4. Initialize programs with several cancer centers, early disease detection clinics, and children’s hospitals in the U.S. to establish the necessary criteria for submission to the FDA.

5. Establish our training standards to create jobs wherein Certified BioHarp technicians can be deployed to hospitals, clinics, and healthcare groups in the U.S. and other countries. This will assist the company in creating opportunities for individuals to be trained and gain successful employment for years to come, either as an employee or for outside healthcare companies.

6. Work closely with several global universities that have expressed a desire to utilize the BioHarp in their studies of crops and plant growth, thereby establishing the BioHarp’s efficacy in assisting nations in their food and fuel productivity through proper scanning using the BioHarp device.

7. Focus on completing the company’s audited financials within the first quarter of 2010 in order to gain a listing on a higher exchange. The company is currently interviewing auditors in order to accomplish the audit in a timely manner.

Our goal is to focus on immediate sales as well as planning the future of the company wherein we capitalize on the many opportunities the BioHarp can bring to XTend Medical,” stated Mr. Paul D. Lisenby, CEO of XTend Medical.

About XTend Medical

XTend Medical is a company that specializes in the sales, manufacturing and distribution of the latest in medical devices and telemedicine solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their recent acquisition of the BioHarp medical device will assist the company in becoming known as a leader in the healthcare sector globally. For further information, please contact them at info@bioharpunius.com or visit their website at www.bioharpunius.com

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.